{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lai YC"],"funding":["Department of Education of Taiwan"],"pagination":["917823"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4055636"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2014"],"pubmed_abstract":["Silencing of acid-labile subunit (ALS) improved glucose metabolism in animal models. The aim of this study is to evaluate the effects of rosiglitazone (RSG) on ALS levels in individuals with type 2 diabetes. A randomized, double-blind, placebo-controlled trial was conducted. Subjects with type 2 diabetes mellitus were randomly distributed to an RSG-treated (n = 30) or a placebo (n = 31) group. Patients were evaluated prior to treatment at baseline and at 12 and 24 weeks after treatment. At baseline, ALS levels were negatively associated with low-density lipoprotein cholesterol (LDLc) levels and homeostatic model assessment version 2 insulin sensitivity (HOMA2-%S). Over 24 weeks, there was a significantly greater reduction in ALS levels in the nonobese RSG-treated individuals than placebo-t"],"journal":["PPAR research"],"pubmed_title":["Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone."],"pmcid":["PMC4055636"],"funding_grant_id":["89-B-FA01-1-4"],"pubmed_authors":["Lai YC","Jeng CY","Wu TJ","Chuang LM","Li HY"],"additional_accession":[]},"is_claimable":false,"name":"Correlation of Circulating Acid-Labile Subunit Levels with Insulin Sensitivity and Serum LDL Cholesterol in Patients with Type 2 Diabetes: Findings from a Prospective Study with Rosiglitazone.","description":"Silencing of acid-labile subunit (ALS) improved glucose metabolism in animal models. The aim of this study is to evaluate the effects of rosiglitazone (RSG) on ALS levels in individuals with type 2 diabetes. A randomized, double-blind, placebo-controlled trial was conducted. Subjects with type 2 diabetes mellitus were randomly distributed to an RSG-treated (n = 30) or a placebo (n = 31) group. Patients were evaluated prior to treatment at baseline and at 12 and 24 weeks after treatment. At baseline, ALS levels were negatively associated with low-density lipoprotein cholesterol (LDLc) levels and homeostatic model assessment version 2 insulin sensitivity (HOMA2-%S). Over 24 weeks, there was a significantly greater reduction in ALS levels in the nonobese RSG-treated individuals than placebo-t","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014","modification":"2025-05-29T19:43:18.681Z","creation":"2025-05-29T19:43:18.681Z"},"accession":"S-EPMC4055636","cross_references":{"pubmed":["24966876"],"doi":["10.1155/2014/917823"]}}